AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 7.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 994,084 shares of the company's stock after purchasing an additional 69,557 shares during the quarter. Bank of New York Mellon Corp's holdings in AstraZeneca were worth $73,065,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Banque Transatlantique SA purchased a new position in AstraZeneca during the fourth quarter valued at approximately $26,000. Confluence Investment Management LLC purchased a new position in AstraZeneca during the first quarter valued at approximately $27,000. Mascagni Wealth Management Inc. purchased a new position in AstraZeneca during the fourth quarter valued at approximately $29,000. FNY Investment Advisers LLC purchased a new position in AstraZeneca during the first quarter valued at approximately $29,000. Finally, Highline Wealth Partners LLC raised its position in AstraZeneca by 447.4% during the first quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock valued at $31,000 after acquiring an additional 340 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Price Performance

Shares of AstraZeneca stock traded down $0.68 on Friday, reaching $71.13. The company's stock had a trading volume of 2,729,851 shares, compared to its average volume of 5,279,228. The company has a market capitalization of $220.60 billion, a P/E ratio of 28.57, a PEG ratio of 1.31 and a beta of 0.37. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The stock has a 50-day moving average price of $70.72 and a 200-day moving average price of $70.81. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The business had revenue of $13.59 billion during the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business's revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.06 earnings per share. Analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Berenberg Bank set a $97.00 price target on AstraZeneca in a research report on Wednesday. BNP Paribas started coverage on AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $89.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.